Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is Doing What Most Biotechs...

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is Doing What Most Biotechs Have Not

SHARE

Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) has been seeing a fervor of investor interest recently. CELZ saw more than 200M shares swapped in one day last week. Over the last month, CELZ is seeing a price change of over 150% but the stock overall is on a bear run when you step back for a moment. Over the last six months, the stock has shed half its value, so what has changed recently?

CELZ has two powerful things working for it: it is nearing commercialization and has cleared bad debt from its books. Investors are jumping in as it is quite difficult to do this in the biotech world. In addition, CELZ has already begun marketing its lead CaverStem stem cell procedure for erectile dysfunction in California. Plans are also underway to unveil the procedure at the upcoming American Urological Association conference in May, as part of an effort that seeks to broaden awareness to more clients and users:

“Our cutting-edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm. Our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis,” said Thomas Ichim PhD, Founder and Chief Scientific Officer of CELZ.

Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) trumpets itself as a company that is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment.

It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED. During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment.

The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.

According to company materials, “Creative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ.”

Find out when $CELZ stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Similar to Viagra in its function, CELZ is seeing an opportunity in the urology market for a subset of the male population that does not react to Viagra or Cialis. This subset is not small – 30 million men are resistant to the two well known erectile dysfunction options. CELZ has a huge opportunity here and the urology community has been warm to the company because the drug allows them now to target everyone.

Furthermore, aside from the erectile dysfunction sector, CELZ has moved to expand its business portfolio in the medical space. The company has formed a new subsidiary dubbed CerebroStem LLC  that will focus on the use of stem cell to treat brain injuries and neurodegenerative diseases.

The subsidiary will initially focus on the treatment of radiation-induced brain damage, a significant cause of cognitive dysfunction in brain cancer patients. The unit will also pursue other areas of brain degeneration, including stroke and Parkinson disease.

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) has a market cap of $2.27M and a float of 63.87M. CELZ is seeing 10-day volume on average at 87.7M. The biotech company is watching stem-cell technology gain legitimacy around it and needs to stay the course to capitalize. CELZ has serious opportunity here but needs more hard evidence to really advance past some of its key support levels. Sign-up for continuing coverage on shares of $CELZ stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CELZ, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter